



A common genetic variant within *SCN10A* modulates cardiac *SCN5A* expression

Malou van den Boogaard,¹ Scott Smemo,² Ozanna Burnicka-Turek,^{3,4} David E. Arnolds,^{3,4} Harmen J.G. van de Werken,⁵ Petra Klous,⁶ David McKean,⁷ Jochen D. Muehlschlegel,⁸ Julia Moosmann,⁹ Okan Toka,⁹ Xinan H. Yang,^{3,4} Tamara T. Koopmann,¹⁰ Michiel E. Adriaens,¹⁰ Connie R. Bezzina,¹⁰ Wouter de Laat,⁶ Christine Seidman,⁷ J.G. Seidman,⁷ Vincent M. Christoffels,¹ Marcelo A. Nobrega,² Phil Barnett,¹ and Ivan P. Moskowitz^{2,3,4}

¹Department of Anatomy, Embryology and Physiology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.

²Department of Human Genetics, ³Department of Pediatrics, and ⁴Department of Pathology, University of Chicago, Chicago, Illinois, USA.

⁵Department of Cell Biology, Erasmus Medical Center, Rotterdam, The Netherlands. ⁶Institute-KNAW and University Medical Center Utrecht, Utrecht, The Netherlands. ⁷Department of Genetics, Harvard Medical School, Boston, Massachusetts, USA.

⁸Department of Anesthesiology, Perioperative and Pain Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA. ⁹Department of Pediatric Cardiology, Children's Hospital University of Erlangen-Nuremberg, Erlangen, Germany.

¹⁰Department of Clinical and Experimental Cardiology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.

Variants in *SCN10A*, which encodes a voltage-gated sodium channel, are associated with alterations of cardiac conduction parameters and the cardiac rhythm disorder Brugada syndrome; however, it is unclear how *SCN10A* variants promote dysfunctional cardiac conduction. Here we showed by high-resolution 4C-seq analysis of the *Scn10a-Scn5a* locus in murine heart tissue that a cardiac enhancer located in *Scn10a*, encompassing *SCN10A* functional variant rs6801957, interacts with the promoter of *Scn5a*, a sodium channel-encoding gene that is critical for cardiac conduction. We observed that *SCN5A* transcript levels were several orders of magnitude higher than *SCN10A* transcript levels in both adult human and mouse heart tissue. Analysis of BAC transgenic mouse strains harboring an engineered deletion of the enhancer within *Scn10a* revealed that the enhancer was essential for *Scn5a* expression in cardiac tissue. Furthermore, the common *SCN10A* variant rs6801957 modulated *Scn5a* expression in the heart. In humans, the *SCN10A* variant rs6801957, which correlated with slowed conduction, was associated with reduced *SCN5A* expression. These observations establish a genomic mechanism for how a common genetic variation at *SCN10A* influences cardiac physiology and predisposes to arrhythmia.

Introduction

Genome-wide association studies (GWAS) on ECG measures in diverse populations have consistently associated noncoding genetic variants within introns of the voltage-gated sodium channel gene *SCN10A* with cardiac conduction system (CCS) function (1–9). Recent work associated noncoding variants at *SCN10A* with Brugada syndrome, a cardiac rhythm disorder with a high risk of sudden death (10). The implication of *SCN10A*, which had not been previously studied in the heart, in cardiac rhythm parameters and Brugada syndrome by GWAS (Figure 1A) was unexpected. Given the position of the associated variants within the gene, including one whose minor allele caused a nonsynonymous substitution in *SCN10A*, it was assumed that the variants were functionally connected with Na_v1.8, the protein product of *SCN10A*. However, functional follow-up analysis of *SCN10A* provided conflicting evidence about whether Na_v1.8 accelerates (5) or slows (2) conduction velocity, and the magnitude of the effects of blocking *Scn10a* in mice was small (2, 5). Therefore, the role of *SCN10A* in cardiac physiology remained controversial (11–13).

Interestingly, *SCN10A* maps immediately adjacent to *SCN5A* (encoding Na_v1.5) on chromosome 3p22.2. In contrast to

SCN10A, *SCN5A* has a well-described role in cardiac physiology and pathophysiology (14–18). CCS function is exquisitely sensitive to Na_v1.5 dose, and heterozygous mutations in *SCN5A* underlie numerous human conduction system diseases, including Brugada syndrome, long QT syndrome, atrial fibrillation, progressive cardiac conduction disease, and sudden cardiac death (14, 19, 20). Furthermore, noncoding variants within introns and downstream of *SCN5A* have also been associated with ECG parameters in GWAS.

We recently demonstrated the importance of the T-box transcription factors *Tbx5* and *Tbx3* in the regulation of *Scn5a* in mice (21, 22). The rapid conducting portions of the CCS require high levels of Na_v1.5 for function (23). Strong *Scn5a* expression is driven in the fast conduction system by TBX5, a transcriptional activator (22). Conversely, repression of *Scn5a* is a key feature ensuring the slow propagation of the cardiac electrical impulse across the sinus node and atrioventricular node (17, 23). TBX3, a transcriptional repressor, plays a major role in the repression of *Scn5a* expression in slowly conducting nodal regions of the developing heart (24, 25). We previously investigated the gene regulatory landscape at the *Scn10a-Scn5a* cluster and identified 2 T-box-regulated enhancers, one positioned downstream of *Scn5a* and the other in an intron of *Scn10a*. A SNP, rs6801957, associated with QRS prolongation and in linkage disequilibrium (LD) with variants associated with Brugada syndrome (5, 10) is located in the *Scn10a* intronic enhancer. This SNP modulates T-box factor binding and activity of the isolated enhancer fragment (21).

Authorship note: Malou van den Boogaard, Scott Smemo, Ozanna Burnicka-Turek, and David E. Arnolds contributed equally to this work. Vincent M. Christoffels, Marcelo A. Nobrega, Phil Barnett, and Ivan P. Moskowitz are co-senior authors.

Conflict of interest: The authors have declared that no conflict of interest exists.

Citation for this article: *J Clin Invest.* 2014;124(4):1844–1852. doi:10.1172/JCI73140.




Figure 1

Contact profiles of enhancers and promoters of the *Scn10a-Scn5a* locus in combination with ChIP-seq data. **(A)** UCSC genome browser view of chr3:38,465,426–38,861,154 (hg18), demonstrating distinct LD blocks within the *SCN10A-SCN5A* locus with SNPs tagged in GWAS studies (green) (1–9). **(B)** Mouse region (mm9; chr9:119,303,698–119,662,489) depicted with 4C analysis showing contact profiles of EnhA in *Scn10a* (blue), *Scn5a* promoter C (green), and EnhB downstream of *Scn5a* (red). Blue, green, and red arrows correspond to the position of the different viewpoints. Black arrows represent the position of the promoter of *Scn10a* and alternate promoters of *Scn5a* (promoters A and B). From the EnhA viewpoint, interactions can be observed between EnhA, EnhB, and the *Scn5a* promoter regions. From the *Scn5a* promoter C viewpoint, contacts can be observed with EnhA and EnhB and weakly with the *Scn10a* promoter region. From EnhB, contacts with the *Scn5a* promoter region and, weakly, with EnhA can be seen. See Supplemental Figure 1 for quantitative assessment of these interactions. **(C)** UCSC genome browser views of ChIP-seq data of the TBX3 (21) and of Pol2 and p300 (27–29) binding profiles aligned with the 4C traces, showing the correspondence between contacts and factor occupancy. **(D)** Model for the interactions of EnhA (blue) and EnhB (red) with the *Scn5a* and *Scn10a* promoters (green and gray, respectively). The promoter of flanking gene *Exog* does not interact.

We investigated the novel hypothesis that genetic variation at *SCN10A* associated with cardiac rhythm disease and conduction mechanistically functions by modulating *SCN5A* expression. We also tested the hypothesis that the regulatory landscape of *SCN5A* may be regulated by multiple *cis*-regulatory elements spread over long-range distances, including *cis*-regulatory elements within introns of *SCN10A*. In such a scenario, functional SNPs at *SCN10A* associated with conduction parameters and disease may reflect disruption of these regulatory elements causing altered expression of *SCN5A*. Using high-resolution chromatin conformation capture (4C), we demonstrated the intricate association of the *Scn10a* intronic enhancer with the promoters of *Scn5a* and *Scn10a* and the downstream *Scn5a* enhancer. We found that *SCN5A* was expressed at high levels, whereas *SCN10A* was expressed at background levels,

in the adult human and mouse heart by RNA-seq. We found that the *cis*-regulatory element located in *Scn10a* regulated the pattern of *Scn5a* expression in the heart, and that the rs6801957 SNP affected cardiac expression of *Scn5a* using a BAC reporter strategy. Finally, we found a direct correlation of *SCN5A* expression in humans with the presence of the rs6801957 risk-associated SNP in the *SCN10A* intronic enhancer. Together, our data provided a genomic mechanism explaining how common genetic variants at *SCN10A* influence cardiac physiology and predispose to arrhythmia.

Results

High-resolution 4C-seq reveals interactions between an enhancer in Scn10a and the Scn5a promoters. We previously identified 2 regions with conserved enhancer activity able to autonomously drive




Figure 2

Scn5a and *Scn10a* expression analysis. (A) Expression of *Scn5a* in the 12-week-old adult mouse heart was 145-fold higher than that of *Scn10a* (53.81 ± 5.39 versus 0.37 ± 0.08 rpm) by mRNA-seq. (B) CCS expression of *Scn5a* in the 12-week-old adult mouse heart was significantly higher than that of *Scn10a*, whose expression was undetectable by qRT-PCR. All samples were analyzed in triplicate. (C) mRNA-seq analysis of adult human heart tissue. *SCN5A* was expressed 1,357-fold higher than *SCN10A* in the whole heart (326 ± 149 versus 0.24 ± 0.22 rpm), 1,753-fold higher in the atria (205 ± 138 versus 0.12 ± 0.18 rpm), and 1,299-fold higher in the ventricles (376 ± 126 versus 0.29 ± 0.21 rpm). Data are mean \pm SD. *** $P < 0.001$, Student's *t* test.

expression of a reporter construct in the murine CCS (21, 22). The region termed enhancer A (EnhA) spans 2 adjacent introns and 1 exon in *Scn10a*, and enhancer B (EnhB) is positioned 15 kbp downstream of *Scn5a* (Figure 1B). EnhA contains a SNP previously found to be associated with QRS prolongation (5). This SNP disrupts a T-box factor binding site that affects EnhA activity in a zebrafish assay (21). Enhancers regulate gene expression by physically interacting with the promoter of a gene. We used the newly developed tool high-resolution 4C-seq (26) to investigate on a genome-wide scale which gene promoters are contacted by EnhA and EnhB, and which genomic regions are contacted by the promoters of *Scn5a* and *Scn10a* (Figure 1B). We aligned 4C-seq with cardiac ChIP-seq data for TBX3 (21) as well as for Pol2 and p300 (27–29) to visualize interactions for EnhA and EnhB (Figure 1C). By setting 4C bait regions around 2 known promoter regions for *Scn5a*, we found that both EnhA and EnhB possessed clear *cis* interactions with the *Scn5a* and *Scn10a* promoters (Figure 1, B and C, and Supplemental Figure 1; supplemental material available online with this article; doi:10.1172/JCI73140DS1). Moreover, contacts between *Scn5a* promoters A and B and the *Scn10a* promoter were observed. When observed from bait sets in the enhancers themselves, EnhA was found to associate with the *Scn5a* and *Scn10a* promoters and the EnhB region, and EnhB was found to associate with the *Scn5a* promoter region and EnhA. These interaction results revealed that EnhA (in *Scn10a*) and EnhB (downstream of *Scn5a*) interacted with both promoters and with each other, which indicates that the enhancers and promoters form a complex (Figure 1D). This topology, in which both enhancers and gene promoters are in close contact, suggests that both enhancers are potential regulators of *Scn5a* and *Scn10a*. This is consistent with the observation that both genes show similar spatial patterns of expression in the fetal heart (21). Furthermore, these data indicate that the variants identified in cardiac rhythm and disease GWAS in EnhA may affect the regulation of *Scn5a*, a dosage-sensitive regulator of cardiac conduction (Figure 1D).

Substantial SCN5A transcripts, but not SCN10A transcripts, in the adult mouse and human heart. In the fetal heart, expression of cardiac *Scn5a* is much higher than that of *Scn10a* (21), which indicates that the contribution of *Scn10a* to the sodium current before birth is small. To evaluate the expression levels of *Scn5a* and *Scn10a* in

the adult, we performed RNA-seq on whole mouse hearts (30). We found that *Scn5a* expression was 145-fold higher than *Scn10a* expression (53.81 ± 5.39 versus 0.37 ± 0.08 reads per million [rpm]; Figure 2A). Therefore, *Scn10a* expression in the heart as a whole was considered to be at background levels. Nevertheless, it remained conceivable that *Scn10a* expression was present in the limited subset of CCS cells based on the pattern of *Scn10a* expression before birth (21). We therefore evaluated *Scn5a* and *Scn10a* expression in the atrioventricular bundle from adult mouse hearts microdissected at 6 weeks of age (Figure 2B). We confirmed the anatomic specificity of isolated tissue, observing robust expression of *Gja5* (also known as *Connexin40*), a gene whose expression in the ventricles is limited to the conduction system (31, 32). In the atrioventricular bundle, expression of *Scn5a* was high, whereas *Scn10a* expression was undetectable (Figure 2B).

We next evaluated *SCN5A* and *SCN10A* expression from human heart samples by RNA-seq (Figure 2C). *SCN5A* expression was more than 1,000-fold greater than *SCN10A* expression in the whole heart, atria, and ventricles (whole heart, 326 ± 149 versus 0.24 ± 0.22 rpm, $P = 2.5 \times 10^{-27}$; atria, 205 ± 138 versus 0.12 ± 0.17 rpm, $P = 1.0 \times 10^{-3}$; ventricles, 376 ± 126 versus 0.29 ± 0.21 rpm, $P = 1.1 \times 10^{-26}$; Figure 2C). The absolute magnitude of *SCN10A* expression, less than 1 part per million, corresponded to a cellular content of less than 1 *SCN10A* RNA molecule per 2 cells (33–35) and qualified as not expressed in the heart (30). These data indicated that *SCN5A* but not *SCN10A* is expressed at appreciable, physiologically relevant levels in the heart. Therefore, we hypothesized that GWAS SNPs in noncoding regions at the *SCN10A* locus affecting cardiac conduction (2–5) modulate *SCN5A* expression.

The enhancer in Scn10a is required for expression of Scn5a in vivo. We tested the hypothesis that both EnhA and EnhB are necessary for endogenous *Scn5a* expression by engineering a BAC reporter system for *Scn5a* in the mouse. Specifically, we used recombining strategies (36) to replace the endogenous first *Scn5a* coding exon with the *LacZ* reporter gene in mouse BAC RP23-198L19. This *Scn5a-LacZ* BAC included the entire *Scn5a* coding region, EnhA, and EnhB (Figure 3A). Independent transgenic lines carrying the WT *Scn5a-LacZ* reporter BAC RP23-198L19 showed a pattern of *LacZ* expression highly reminiscent of endogenous *Scn5a* expression (17, 21), including reproducible expression in structures of




Figure 3

EnhA and EnhB are necessary for *Scn5a* cardiac expression. (A) Modified murine BAC RP23-198L19 with *LacZ* inserted into the endogenous *Scn5a* translational start site. (B–F) Stable BAC transgenic lines, shown in whole-mount and cross-section histology; arrows indicate AV bundle (blue) and distal bundle branches (red). Pie charts show the distribution of *LacZ* expression in each genotype class. All studies were performed at 12 weeks of age; the number of independent transgenic lines examined is indicated (each analyzed in triplicate). (B) The WT enhancer demonstrated robust CCS and myocardial expression. (C) EnhA deletion eliminated proximal CCS and myocardial expression. (D) EnhB deletion eliminated distal CCS and myocardial expression. (E) Deletion of both enhancers eliminated CCS and myocardial expression entirely. (F) The minor allele at rs6801957 markedly altered *Scn5a-LacZ* expression, which was either entirely absent or absent from the atrioventricular bundle and confined to the distal ventricular septum in the majority of cases.

the ventricular conduction system including the atrioventricular bundle and ventricular myocardium in adult (3 of 3) and embryonic (6 of 6) hearts (Figure 3B, Supplemental Figure 2, A–F, and Supplemental Figure 4A).

To investigate the necessity of EnhA and EnhB for *Scn5a-LacZ* reporter expression, we engineered deletions of EnhA (chr9:119,540,800–119,544,032), EnhB (chr9:119,378,051–119,379,479), or both from the BAC reporter and then evaluated *Scn5a-LacZ* expression in vivo. Removal of EnhA alone significantly abrogated *Scn5a-LacZ*: expression of *LacZ* was absent from ventricular myocardium in all independent adult and embryonic EnhA deletion BAC transgenics (Figure 3C, Supplemental Figure 2, G–O, and Supplemental Figure 4B). *LacZ* expression was disrupted

in the CCS in the majority of EnhA deletion BAC transgenics. When present, *LacZ* expression was confined to the distal ventricular septum (Figure 3C, Supplemental Figure 2, G–O, and Supplemental Figure 4B). Removal of EnhB alone also substantially altered and reduced *LacZ* expression from the *Scn5a* locus (Figure 3D, Supplemental Figure 2, P–V, and Supplemental Figure 4C). Interestingly, the region of ventricular CCS *Scn5a-LacZ* expression that was maintained in EnhB deletion BAC transgenics (Figure 3D, Supplemental Figure 2, R–T, and Supplemental Figure 4C) was reciprocal to that maintained in EnhA deletion BAC transgenics (Figure 3C, Supplemental Figure 2, H–J, and Supplemental Figure 4B). Removal of both EnhA and EnhB together completely eliminated *Scn5a-LacZ* expression in all independent adult and




Figure 4 SNP rs6801957 modulates EnhA activity. Transient transgenic embryos at E14.5 harboring human 2.2-kb EnhA with major (A) and minor (B) allele of SNP rs6801957. Human EnhA with the major allele (n = 9) was sufficient to drive CCS expression (A), but human EnhA with the minor allele (n = 4) was not (B). (C) Correlation of *SCN5A* expression in human hearts with SNP rs6801957 genotype. *SCN5A* expression was assessed by RNA-seq in 42 human cardiac tissue samples, of which 19 were homozygous GG, 18 were heterozygous GA, and 6 were homozygous AA at locus rs6801957. Homozygous GG individuals had significantly higher *SCN5A* expression (428 ± 128 rpm) than GA (331 ± 104 rpm) or AA (322 ± 66 rpm) individuals. Each A allele reduced expression by 12% ± 6% (P = 0.01). A linear additive regression model was used to determine statistical significance. Lines within boxes represent median value; boxes represent interquartile range; whiskers represent 5th and 95th percentiles.

embryonic transgenics (Figure 3E, Supplemental Figure 2, W-AC, and Supplemental Figure 4D). Taken together, these observations demonstrated that EnhA and EnhB are necessary and sufficient for in vivo *Scn5a* expression.

The SNP rs6801957, associated with conduction slowing in GWAS, leads to lower *SCN5A* expression in mice and in humans. The observation that EnhA, which is located in *Scn10a*, was required for *Scn5a* expression suggested that common genetic variation affecting conduction system physiology and disease at *SCN10A* may modify *SCN5A* expression. A sentinel SNP located in *SCN10A* for conduction system physiology, rs6801957 (5), lies within EnhA (Figure 1A and Figure 3A). The major allele for rs6801957, G, establishes a conserved canonical T-box binding site (GGT \underline{G} ACAG) and promotes enhancer activity, whereas the minor allele A, associated with conduction slowing, disrupts a core nt in the T-box site (GGT \underline{A} ACAG) and decreases enhancer activity (21). This SNP is in strong LD with the nonsynonymous *SCN10A* SNP evaluated in prior studies (rs6795970, HapMap 2 CEU population, D' = 1.0, r² = 0.96, refs. 2, 3), with 2 other SNPs that implicated *SCN10A* in cardiac physiology in independent studies (rs6800541, HapMap 2 CEU population, D' = 1.0, r² = 0.96, ref. 4; rs6798015, HapMap 2 CEU population, D' = 0.955, r² = 0.84, ref. 1), and with the SNP that implicated *SCN10A* in Brugada syndrome (rs10428132, HapMap 2 CEU population, D' = 1.0, r² = 0.97, ref. 10) (Figure 1A).

We tested the allele-specific effects of the murine nt orthologous to SNP rs6801957 on *Scn5a* expression. The rs6801957 minor allele (A) was recombineered into the orthologous region of the *Scn5a-LacZ* BAC, and *LacZ* expression was analyzed in adult murine hearts (Figure 3F, Supplemental Figure 3, and Supplemental Figure 4E). The minor allele at rs6801957 substantially altered *Scn5a-LacZ* expression: expression of *LacZ* was markedly disrupted in the

compact myocardium of the majority of independent transgenics (Figure 3F, Supplemental Figure 3, and Supplemental Figure 4E). *LacZ* expression was also significantly disrupted in the CCS of the majority of independent adult (4 of 6) and half of embryonic (8 of 16) transgenics (P = 0.04; Figure 3F, Supplemental Figure 3, and Supplemental Figure 4E). We concluded that the risk allele orthologous to SNP rs6801957 substantially decreased *Scn5a* expression and, conversely, that the major allele orthologous to SNP rs6801957 is necessary for normal CCS *Scn5a* expression.

We next tested whether rs6801957 affects the sufficiency of human EnhA sequences to drive CCS expression in transgenic mice in vivo (Figure 4). Human EnhA with the major allele of rs6801957 was sufficient to drive *Scn5a-LacZ* expression in myocardium and the CCS in the majority of transient transgenic mouse embryos (Figure 4A). However, EnhA with the minor allele was insufficient for cardiac expression (P = 0.05; Figure 4B). We concluded that the major allele of SNP rs6801957 is necessary for normal CCS activity of EnhA.

We hypothesized that rs6801957 influenced *SCN5A* expression in humans. Therefore, we evaluated *SCN5A* mRNA levels as a function of genotype at this SNP in 2 independent heart tissue biobanks by RNA-seq and quantitative real-time RT-PCR (qRT-PCR). In the first set, GG samples (homozygous for the major allele associated with shorter PR and QRS intervals) expressed substantially more *SCN5A* mRNA (428 ± 128 normalized rpm; n = 19) than GA (331 ± 104 rpm; n = 18) or AA (322 ± 66 rpm; n = 6) tissue samples. In this set, each additional copy of the A allele reduced cardiac *SCN5A* expression by 12% ± 6% (additive genetic model, P = 0.01; dominant genetic model, P = 0.01). *SCN10A* was not appreciably expressed in any genotype. In the second set, samples homozygous for GG at rs6801957 expressed significantly more *SCN5A*



RNA (0.060 ± 0.029 normalized expression; $n = 33$) than GA (0.048 ± 0.017 normalized expression; $n = 37$) or AA (0.050 ± 0.028 normalized expression; $n = 17$) tissue samples (additive genetic model, $P = 0.11$; dominant genetic model, $P = 0.03$). In this set, although the level of *SCN5A* mRNA did not increase linearly per copy of G allele, genotype at rs6801957 was significantly associated with *SCN5A* mRNA levels with the same direction of effect as in the first sample set. *SCN10A* variant rs6801957 had no detectable effect on *SCN10A* expression, although power to detect allele specific expression on *SCN10A* would be very poor, given its low expression in adult cardiac tissue.

Discussion

Our results unveil the genomic regulatory logic controlling *Scn5a* expression, with implications for interpreting cardiac GWAS and understanding the genomic basis of CCS function and disease. The physical associations between enhancers and promoters at the *Scn10a-Scn5a* locus were analyzed by 4C, a technique that provides a genome-wide view of all *cis* interactions (26, 37). Viewpoints from both EnhA and EnhB revealed interactions with the *Scn5a* and *Scn10a* promoter regions and, additionally, multiple contact points in and beyond *Scn5a*, fitting with ChIP-seq data. These contacts were confirmed when taking the promoters as viewpoint. Our findings indicate that the enhancers and promoters at this locus are all in close proximity, allowing the enhancers to simultaneously interact with and potentially regulate the transcription of both *Scn5a* and *Scn10a*. A conserved genomic architecture that enables enhancer sharing and coregulation of genes within an evolutionary conserved cluster has also been observed for the *Irx* and *Hox* gene clusters (38). Although the enhancers contact the *Scn10a* promoter, quantification of *Scn10a* transcript levels indicated that *Scn10a* transcription was not activated by these enhancers. Therefore, we focused our attention on the functionality of interactions between these enhancers and *Scn5a*. Using BAC transgenesis, an assay complementary to 4C contact mapping, we demonstrated the functionality of the interactions between EnhA and EnhB and *Scn5a*. The enhancers functioned in a modular pattern to determine *Scn5a* expression: EnhA, located in *Scn10a*, was required for proximal ventricular CCS expression; EnhB, located downstream of *Scn5a*, was required for distal ventricular CCS expression; and both enhancers were required for ventricular myocardium expression.

Our data indicate that the physiological role underlying common variants at *SCN10A* in cardiac rhythm control is not ascribed to the *SCN10A* gene product $\text{Na}_v1.8$, but instead to the *SCN5A* gene product $\text{Na}_v1.5$. SNPs identified by GWAS have modest effect sizes, an attribute inherent to their common frequency (39). This suggests that noncoding SNPs associated with human phenotypes by GWAS may cause expression alterations to genes with dosage-sensitive physiology. This paradigm held only for *SCN5A*, not *SCN10A*. *SCN5A* has an exquisitely dosage-sensitive relationship to ECG parameters and cardiac rhythm control. Heterozygous mutations in human *SCN5A* underlie numerous human conduction system diseases, including Brugada syndrome, long QT syndrome, atrial fibrillation, progressive cardiac conduction disease, and sudden cardiac death (14, 19, 20). Furthermore, noncoding variants within introns and downstream of *SCN5A* have also been associated with ECG parameters in GWAS. The mouse homozygous null phenotype is embryonic lethal, and mice haploinsufficient for *Scn5a* display a host of profound cardiac rhythm distur-

bances, including slowed cardiac conduction and a Brugada-like phenotype, similar to those associated with SNPs at neighboring *SCN10A* (2, 5). In contrast, whether the *SCN10A* product $\text{Na}_v1.8$ plays a role in cardiac physiology remains controversial (11–13). The *Scn10a* knockout mouse displayed subtle cardiac ECG abnormalities, including modest PR interval shortening indicative of more rapid than normal conduction (2). This phenotype is at odds with the role of voltage-gated sodium channels in the rapid phase of myocardial depolarization, in which a decrease in channel function and concomitant sodium current would slow conduction (as observed by lowering *Scn5a* expression). Moreover, functional analysis of *Scn10a* indicated that the effects of pharmacologically blocking or genetically inactivating *Scn10a* are small, and provided conflicting evidence about whether $\text{Na}_v1.8$ accelerates (5) or slows (2) conduction velocity. Expression analysis also supports a more substantial role for the gene product of *Scn5a* than that of *Scn10a*. During embryonic development, low levels of *Scn10a* expression can be qualitatively observed using in situ hybridization (21, 22) and qRT-PCR, demonstrating expression levels 4–5 times lower than those of *Scn5a*. However, as development progressed to adult stages, *Scn10a* expression remained low, whereas *Scn5a* transcript levels were induced to levels 100-fold greater than those of *Scn10a*. In humans, the expression discrepancy was 1,000-fold in favor of *SCN5A* over *SCN10A*. Although transcripts for both genes could be detected in heart tissue by PCR-based approaches, the confluence of data — including our *SCN10A* transcript quantification in adult heart tissue, our genotype-*SCN5A* expression correlation, and physiological observations of *Scn10a* knockout mice by others (2) — suggest that the contribution of $\text{Na}_v1.8$ to cardiac physiology is minor. The absence of substantial effects in the *Scn10a* knockout, combined with the dramatic effects on electrophysiology observed for *Scn5a* knockout models (16, 18, 40), supports the contention that common genetic variation at the *SCN10A* locus affects cardiac physiology via dysregulation of *SCN5A* expression. Our observations do not formally rule out the possibility of other mechanisms affecting conduction physiology at the *SCN10A-SCN5A* locus. However, the totality of the evidence, including our present observations, strongly supports the relevance of the genomic mechanism we describe to cardiac conduction physiology and arrhythmia risk.

Mechanistically connecting noncoding genetic variations to their associated traits requires a commitment to understanding the functional biology of *cis*-regulatory elements, given that up to 85% of GWAS SNPs associated with human disease traits are noncoding (41, 42). Here, we presented an integrative and comprehensive experimental strategy to functionally link noncoding variants mapping within long-range *cis*-regulatory elements to their target genes. Combining high-resolution 4C strategies with engineering of BACs and mouse transgenic reporter assays, we demonstrated that the regulatory landscape of *SCN5A* extended into *SCN10A* and that the ECG-associated SNPs within *SCN10A* modified the function of an *SCN5A* enhancer. Using genomics and genetics data, we further demonstrated that these SNPs were associated with expression of *SCN5A*, but not *SCN10A*, in human hearts. Together, our data established *SCN5A* as the functional target of the noncoding variants within *SCN10A* associated with ECG parameters. The present work provides a genomic mechanism for the effect of common genetic variants at *SCN10A* on cardiac physiology and disease and provides a strong rationale for careful interrogation of the noncoding activity of GWAS variants prior to



ascribing function to annotated genes. Our findings also suggest a genomic pathophysiological mechanism for Brugada syndrome, with the potential to refine diagnosis and implications for future therapeutic approaches.

Methods

Experimental animals

Generation of *Scn5a-LacZ* BAC transgenic mice was performed by the University of Chicago Transgenic Core Facility by pronuclear microinjection of DNA. Mice were maintained on a mixed genetic background and analyzed at E13.5, E14.5, and 12 weeks of age. All experiments used age-, gender-, and genetic strain-matched controls to account for any variations in data sets compares across experiments. Mice were bred and housed in specific pathogen-free conditions in a 12-hour light/12-hour dark cycle and allowed ad libitum access to standard mouse chow and water. Mice requiring medical attention were provided with appropriate veterinary care by a licensed veterinarian and were excluded from the experiments described. No other exclusion criteria existed.

4C template preparation

4C templates were prepared as previously described (43). In short, adult mouse hearts were isolated in ice-cold PBS. Single-cell suspensions were obtained by dissociation of tissue with IKA Ultra Turrax T5 FU, followed by dounce homogenization. Chromatin was cross-linked with 2% formaldehyde in PBS with 10% FCS for 10 minutes at room temperature, nuclei were isolated, and cross-linked DNA was digested with a primary restriction enzyme recognizing a 4-bp restriction site (DpnII), followed by proximity ligation. Cross-links were removed, and a secondary restriction enzyme digestion (Csp6I) was performed, followed again by proximity ligation. For all experiments, 200 ng of the resulting 4C template was used for the subsequent PCR reaction, of which 16 (total, 3.2 μ g of 4C template) were pooled and purified for next-generation sequencing. The PCR products were purified using 2 columns per sample of the High Pure PCR Product Purification Kit (catalog no. 11732676001; Roche). The kit separates the PCR products larger than 120 bp from the adaptor-containing primers (~75 and ~40 nt in size). Similar results were obtained with products from a single PCR reaction (200-ng template).

4C-seq primer design

PCR primers were designed based on the following criteria. The size of the viewpoint fragment was at least 500 bp, to allow efficient cross-linking to other DNA fragments. The fragment end (the region between the primary and secondary restriction enzyme) was more than 350 bp, to allow efficient circularization during the second ligation step. Primers were designed to be maximally 20 nt in length. The strategy therefore produces sequencing reads (36 mers in this study) composed of the 4C primer sequence (20 nt, specific to a given viewpoint) followed by 16 nt that identify a captured sequence. The reading primer always hybridizes to, and ends at, the 3' side of the first restriction recognition site. This design ensures analysis of only primary ligation events and provides sufficient sequence information to unambiguously identify most captured sequences. The nonreading primers, 18–20 nt in size, were designed at a distance \leq 100 bp from the secondary restriction site. All primers had 35%–65% GC content and an optimal basic temperature of 55°C, ranging 45°C–65°C. Primers were checked against the mouse genome with MegaBLAST23 (settings, -p 88.88, -W 12, -e 1, -F T), which requires primers on the reading side to be matched uniquely in the genome and primers on the nonreading side to have a maximum of 3 perfectly matching BLAST high-scoring segment pairs (HSP). See Supplemental Table 1 for all primers used.

4C data analysis and statistics

4C templates were mixed and sequenced simultaneously in 1 Illumina HiSeq 2000 lane. The sequence tags generated by the procedure were prefixed by the 4C reading primer, which includes the DpnII restriction site sequence (see 4C-seq primer design). The 4C reading primer sequences were separated from multiplexed 4C-seq libraries, and the suffixes were extracted for further processing. Mapping and filtering of the sequence reads was done as previously described (26). The algorithm constructs a background model for remote intra- and interchromosomal contacts to correct for systematic biases that can occur during the 4C-seq experimental protocol. The algorithm is designed to use controls for sequencing errors and nonunique sequences while considering the high coverage (100 \times –100,000 \times) of fragment ends that are proximal to the viewpoint fragment. To normalize the interactions in close proximity to the viewpoint, the algorithm was used to calculate the median of normalized coverage for running windows of size 4 kb (depicted as black line) and sliding windows of 2–50 kb of linearly increasing size (depicted as color-coded multiscale diagrams). All median values represent enrichment relative to the maximum attainable 4-kb median value, whereas sliding windows represent enrichment relative to the maximum attainable 12-kb median value. The 20th and 80th percentiles were also computed and depicted as the green area around the 4-kb running windows (Supplemental Figure 1).

mRNA-seq and genotyping rs6801957

Ventricular tissue set 1. Human left ventricular samples ($n = 39$) were obtained from patients of mixed ancestry who were given left ventricular assist devices. Discarded left ventricular tissue was obtained at the time of insertion of the device. Human right atrial samples ($n = 4$) were obtained as discarded tissue from patients who had cardiac surgery to repair their congenital heart disease lesion. The expression levels of *Scn5a* and *Scn10a* in adult mouse and human cardiac tissue were assessed by RNA-seq as described previously (30, 33–35). Samples were blinded to genotype at the SCN locus. Post-hoc analyses showed that there was no association between lane or batch and expression of *SCN5A* or *SCN10A* expression, independent of genotype. The rs6801957 genotype was assessed by dideoxy sequencing of PCR-amplified genomic DNA using standard procedures (44). rs6801957 sequences were amplified using the following primers: primer A, CACCTG-GAGCTCCCTAAGA; primer B, GAGTCTGTAGCTCTCCCATAG. Primer A was used as sequencing primer. A linear additive regression model was used to determine statistical significance (45).

Ventricular tissue set 2. Human left ventricular samples ($n = 129$) were collected from nonimplanted human donor hearts that were considered suitable for transplantation, yet not used due to logistical reasons. All heart samples used in this study were from individuals of self-reported European descent and were collected at centers in Szeged (gift from A. Varro, University of Szeged, Szeged, Hungary), Sydney (gift from C. dos Remedios, University of Sydney, Sydney, Australia), Miami (gift from N.H. Bishopric, University of Miami School of Medicine, Miami, Florida, USA), and Vanderbilt (gift from A.L. George, Vanderbilt University, Nashville, Tennessee, USA). Samples were flash-frozen and stored in liquid nitrogen. RNA and DNA were isolated from cardiac tissue following standard protocols. Manhattan distance hierarchical clustering using genome-wide SNP genotypic data confirmed a genetically homogeneous group. Genotype at rs6801957 was determined by means of a Taqman assay (Applied Biosystems). cDNA was prepared using Oligo-dT and ThermoScript First-Strand Synthesis System (Invitrogen) and used for qRT-PCR for determination of *SCN5A* transcript levels. All qRT-PCR assays were performed in triplicate. Expression values were normalized by dividing by the geometric mean of *HPR1* and *TNNI3* mRNA expression values (46). For each set of triplicates, the mean, SD, and coefficient of



variation were calculated. Sets with a coefficient of variation higher than 0.20 were left out of the analysis, as previously described (47), leaving a total of 87 subjects for analysis. The association between rs6801957 and *SCN5A* transcript levels (Supplemental Figure 5) was tested using an additive and dominant genetic model, taking gender, age, and center of origin as covariates. All calculations were performed in statistical programming language R, version 2.15.3.

BAC modification

Mouse BAC RP23-198L19 (mm9; chr9:119,351,100–119,598,458) was engineered in vitro using recombineering kits and protocols from Gene Bridges GmbH (Heidelberg). BAC RP23-198L19 was converted into an *Scn5a* transcriptional reporter (*Scn5a-LacZ*) by inserting a *LacZ*-ampicillin cassette, in frame, replacing the first exon of *Scn5a* using the Red/ET recombination kit and protocol from Gene Bridges (catalog no. K001). Primers used for generation of the recombineering cassette were as follows: *Scn5a*-LAI forward, CTTCCAGGCAGCCTGAGGAGAGCCTGTGCCCCAGAAGCAGGATGAGAAGATGGCTCGCGATGATCCCGTCGT; *Scn5a*-LAI reverse, AGCCTCCTCTCTGGCAGGCCCTCACGGCTCTCCTGTGAGGTGGCCGAACCTCGAGGCTAGCTCTAGAAGTCCAGC. Ampicillin-resistant colonies were PCR screened for homologous recombination using primers in the unaffected genomic region flanking the insertion and within the vector cassette, and the insertion junction was verified by sequencing using the following primers: *Scn5a* 5pI forward, CATCACACCCTGTGTTGTCTC; *Scn5a* 5pI reverse, GGTACTATAGAAAGGGTCCAGGTCT; *Scn5a* 3pI forward, AGAAGATGGCAAACCTCCTGTTC; *Scn5a* 3pI reverse, TGATTGGAATACAGATTAATGGTGA. Recombinant BACs were confirmed intact by restriction digest fingerprinting with PspXI (NEB).

EnhA and EnhB were deleted in the *Scn5a-LacZ* BAC through their targeted replacement, again using the Red/ET recombination kit and protocol from Gene Bridges (catalog no. K001). EnhA (chr9:119,540,801–119,544,032) was replaced with a spectinomycin resistance gene amplified from the iTol2-Amp plasmid using the following primers: *Scn5a* EnhADel forward, CTTAGGCAACCAGCCTGAATAGAAGCTGAAGC-CACACCAGCATTCCAGGGATAAAAATATATCATCATGCCTCCTC; *Scn5a* EnhADel reverse, GGCTCTTTGAAGAATCTGGCACAACCTGTACATGGTCACTGCCTATCTGGTCACGTTAAGGGATTTGGTCA. Insertion site location and fidelity was determined by PCR amplification and sequencing using the following primers flanking and internal to the junction: *Scn5a* EnhADelCheck5p forward, CAAAGGGCAGGTGAGAAGTC; *Scn5a* EnhADelCheck5p reverse, CGAACCGAACAGGCTTATGT; *Scn5a* EnhADelCheck3p forward, CACCAAGGTAGTCGGCAAAT; *Scn5a* EnhADelCheck3p reverse, CTCGGAGGAGCTTGTGTTCAT. EnhB (chr9:119,378,052–119,379,479) was replaced with a kanamycin/neomycin resistance gene amplified from the rpsL-neo plasmid (Gene Bridges kit no. K002), using the following primers: *Scn5a* EnhBDel forward, TGAACCTCAGCTTGTGACAGGTTTGACAGCAAATACCGTTACCGGCCGAGCCAGGCGCTGGTGATGATGGCGGGATC; *Scn5a* EnhBDel reverse, CCTGACTCTTGAGGTACATTCTTGCCCCCTTCCCCCGTCCCCAACGTGATCAGAAGAACCTCGTCAAGAAGGCG. The insertion site was checked with the following flanking/internal primers: *Scn5a* EnhBDelCheck forward, GCTTGT-CAGGTTTGACAGCA; rpsL reverse, CAGACGAACCGCATACTTTAC; Kan forward, ATCAGGATGATCTGGACGAAGAG; *Scn5a* EnhBDelCheck reverse, TGGCCTGACTCTTGAGGTACA.

Recombinant colonies were selected with appropriate antibiotic, and the BAC was confirmed intact by fingerprint analysis with PspXI.

SNP rs6801957, in EnhA, was converted from the major G allele to the minor A allele, without leaving an antibiotic resistance gene behind using the 2-step counter selection BAC modification kit (Gene Bridges

kit no. K002). In the first step, a counter-selection cassette containing a kanamycin resistance and a streptomycin sensitivity gene was inserted into EnhA using primers EnhA MutCsHA1 (CAGAGTTCGTGTTCTTTACTCCCGGGAGGTGACACTCTGGCCTCGGCTGCGGCCTGGTGATGATGGCGGGATCG) and EnhA MutCsHA2 (CTAACAGCTGCTGCTATCAACTATCATTTCGAGATTCCTTTGTCTGAGTTCAGAAGAACTCGTCAAGAAGGCG), resulting in the deletion of rs6801957. Recombinant colonies were selected for with kanamycin, and the insertion site was verified with the following primers: EnhA MutCsSpan forward, AATACACTGCGGGAGGTTTG; rpsL reverse, CAGACGAACCGCATACTTTAC; Kan forward, ATCAGGATGATCTGGACGAAGAG; EnhA MutCsSpan reverse, CCTGAGCCTTCTGATAACG. In the second step, the counter-selection cassette was replaced with a recombineering cassette consisting of an A nt flanked by homology arms of 205 and 290 bp, thereby restoring rs6801957, but with the minor allele. This recombination cassette was generated by first cloning the EnhA region into a pGL3 vector and converting the rs6801957 allele from G to A through traditional mutagenesis techniques, followed by PCR amplification from the EnhA MutCsSpan forward and reverse primers above and DpnI digestion to remove plasmid template. After recombination, colonies retaining the counter-selection cassette were selected against with streptomycin, and 5 of 5 sequenced colonies possessed the A allele. BACs were again checked for length and content using separate restriction digest fingerprints with NotI, PspXI, and EcoRV.

BAC DNA was prepared for pronuclear injection using Nucleobond PC20 Kit (Macherey-Nagel) from a fresh, overnight culture. An aliquot was checked for length and degradation via PFGE, and the remainder was dialyzed against PBS and submitted for pronuclear injection. Pronuclear injections were performed by the University of Chicago Transgenic Core Facility, supported by University of Chicago Cancer Center.

Human enhancer transgenics

Cloning of the human enhancer and testing in transient transgenics was performed as described previously (21).

Statistics

Values represent mean \pm SD of the indicated number of measurements. Statistical significance was determined using 2-tailed Student's *t* test or a linear additive regression model. A *P* value less than 0.05 was considered significant. No statistical method was used to predetermine sample size, and animal experiments were not performed in a blinded fashion. Mice were assigned at random to treatment groups for all mouse studies.

Study approval

All experiments were performed under an University of Chicago IACUC-approved protocol (ACUP no. 71737) and in compliance with US Public Health Service Policy on Humane Care and Use of Laboratory Animals.

Acknowledgments

We thank Nanette H. Bishopric, Alfred L. George, Andras Varro, and Cristobal dos Remedios for providing samples for expression analysis in human donor hearts. The study was funded by grants from the NIH (R01 HL114010, to I.P. Moskowitz and M.A. Nobrega), AHA (10PRE2670012, to D.E. Arnolds), the European Community's Seventh Framework Programme contract ("CardioGeNet" 223463, to V.M. Christoffels), the Cardiovascular Onderzoek Nederland (PRE-DICT, to C.R. Bezzina), the German Foundation for Heart Research (F/09/10, to O. Toka), and the Federal Ministry of Education and Research (BMBF; FKZ01GI0601, to O. Toka).



Received for publication September 26, 2013, and accepted in revised form January 9, 2014.

Address correspondence to: Vincent M. Christoffels or Phil Barnett, Department of Anatomy, Embryology, and Physiology, University of Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands. Phone: 3120.5667821; Fax: 3120.6976177; E-mail: v.m.christoffels@amc.uva.nl (V.M. Christoffels). Phone: 3120.5667822; Fax:

3120.6976177; E-mail: p.barnett@amc.uva.nl (P. Barnett). Or to: Marcelo A. Nobrega, Department of Human Genetics, University of Chicago, 920 E. 58th Street CLSC 319, Chicago, Illinois 60637, USA. Phone: 773.834.7919; Fax: 773.834.8470; E-mail: nobrega@uchicago.edu. Or to: Ivan P. Moskowitz, Departments of Pediatrics and Pathology, University of Chicago, 900 E. 57th Street, KCB, Rm 5118, Chicago, Illinois 60637, USA. Phone: 773.834.0462; Fax: 773.834.2132; E-mail: imoskowitz@uchicago.edu.

1. Smith JG, et al. Genome-wide association studies of the PR interval in African Americans. *PLoS Genet.* 2011;7(2):e1001304.
2. Chambers JC, et al. Genetic variation in SCN10A influences cardiac conduction. *Nat Genet.* 2010;42(2):149–152.
3. Holm H, et al. Several common variants modulate heart rate, PR interval and QRS duration. *Nat Genet.* 2010;42(2):177–122.
4. Pfeufer A, et al. Genome-wide association study of PR interval. *Nat Genet.* 2010;42(2):153–159.
5. Sotoodehnia N, et al. Common variants in 22 loci are associated with QRS duration and cardiac ventricular conduction. *Nat Genet.* 2010;42(12):1068–1076.
6. Denny JC, et al. Identification of genomic predictors of atrioventricular conduction: using electronic medical records as a tool for genome science. *Circulation.* 2010;122(20):2016–2021.
7. Pfeufer A, et al. Common variants at ten loci modulate the QT interval duration in the QTSCD Study. *Nat Genet.* 2009;41(4):407–414.
8. Cho YS, et al. A large-scale genome-wide association study of Asian populations uncovers genetic factors influencing eight quantitative traits. *Nat Genet.* 2009;41(5):527–534.
9. Gudbjartsson DF, et al. Variants conferring risk of atrial fibrillation on chromosome 4q25. *Nature.* 2007;448(7151):353–357.
10. Bezzina CR, et al. Common variants at SCN5A-SCN10A and HEY2 are associated with Brugada syndrome, a rare disease with high risk of sudden cardiac death. *Nat Genet.* 2013;45(9):1044–1049.
11. London B. Whither art thou, SCN10A, and what art thou doing? *Circ Res.* 2012;111(3):268–270.
12. Yang T, Atack TC, Stroud DM, Zhang W, Hall L, Roden DM. Blocking Scn10a channels in heart reduces late sodium current and is antiarrhythmic. *Circ Res.* 2012;111(3):322–332.
13. Verkerk AO, et al. Functional Nav1.8 channels in intracardiac neurons: the link between SCN10A and cardiac electrophysiology. *Circ Res.* 2012;111(3):332–343.
14. Rook MB, Evers MM, Vos MA, Bierhuizen MF. Biology of cardiac sodium channel Nav1.5 expression. *Cardiovasc Res.* 2012;93(1):12–23.
15. Stengl M. Experimental models of spontaneous ventricular arrhythmias and of sudden cardiac death. *Physiol Res.* 2010;59(suppl 1):S25–S31.
16. Leoni AL, et al. Variable Nav(v)1.5 protein expression from the wild-type allele correlates with the penetrance of cardiac conduction disease in the Scn5a(+/-) mouse model. *PLoS One.* 2010;5(2):e9298.
17. Remme CA, et al. The cardiac sodium channel displays differential distribution in the conduction system and transmural heterogeneity in the murine ventricular myocardium. *Basic Res Cardiol.* 2009;104(5):511–522.
18. Papadatos GA, et al. Slowed conduction and ventricular tachycardia after targeted disruption of the cardiac sodium channel gene Scn5a. *Proc Natl Acad Sci U S A.* 2002;99(9):6210–6215.
19. Wilde AA, Brugada R. Phenotypic manifestations of mutations in the genes encoding subunits of the cardiac sodium channel. *Circ Res.* 2011;108(7):884–897.
20. Tfelt-Hansen J, Winkel BG, Grunnet M, Jespersen T. Inherited cardiac diseases caused by mutations in the Nav1.5 sodium channel. *J Cardiovasc Electrophysiol.* 2010;21(1):107–115.
21. van den Boogaard M, et al. Genetic variation in T-box binding element functionally affects SCN5A/SCN10A enhancer. *J Clin Invest.* 2012;122(7):2519–2530.
22. Arnolds DE, et al. TBX5 drives Scn5a expression to regulate cardiac conduction system function. *J Clin Invest.* 2012;122(7):2509–2518.
23. Abriel H. Cardiac sodium channel Na(v)1.5 and interacting proteins: Physiology and pathophysiology. *J Mol Cell Cardiol.* 2010;48(1):2–11.
24. Hoogaars WM, et al. Tbx3 controls the sinoatrial node gene program and imposes pacemaker function on the atria. *Genes Dev.* 2007;21(9):1098–1112.
25. [No authors listed]. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF) *Lancet.* 1999;353(9169):2001–2007.
26. van de Werken HJ, et al. Robust 4C-seq data analysis to screen for regulatory DNA interactions. *Nat Methods.* 2012;9(10):969–972.
27. Shen Y, et al. A map of the cis-regulatory sequences in the mouse genome. *Nature.* 2012;488(7409):116–120.
28. Blow MJ, et al. ChIP-Seq identification of weakly conserved heart enhancers. *Nat Genet.* 2010;42(9):806–810.
29. Visel A, et al. ChIP-seq accurately predicts tissue-specific activity of enhancers. *Nature.* 2009;457(7231):854–858.
30. Sakabe NJ, et al. Dual transcriptional activator and repressor roles of TBX20 regulate adult cardiac structure and function. *Hum Mol Genet.* 2012;21(10):2194–2204.
31. Delorme B, et al. Expression pattern of connexin gene products at the early developmental stages of the mouse cardiovascular system. *Circ Res.* 1997;81(3):423–437.
32. Miquerol L, et al. Architectural and functional asymmetry of the His-Purkinje system of the murine heart. *Cardiovasc Res.* 2004;63(1):77–86.
33. DeLaughter DM, et al. Spatial transcriptional profile of the chick and mouse endocardial cushions identify novel regulators of endocardial EMT in vitro. *J Mol Cell Cardiol.* 2013;59:196–204.
34. Herman DS, et al. Truncations of titin causing dilated cardiomyopathy. *N Engl J Med.* 2012;366(7):619–628.
35. Islam S, et al. Characterization of the single-cell transcriptional landscape by highly multiplex RNA-seq. *Genome Res.* 2011;21(7):1160–1167.
36. Copeland NG, Jenkins NA, Court DL. Recombining: a powerful new tool for mouse functional genomics. *Nat Rev Genet.* 2001;2(10):769–779.
37. de Wit E, de Laat W. A decade of 3C technologies: insights into nuclear organization. *Genes Dev.* 2012;26(1):11–24.
38. Tena JJ, et al. An evolutionarily conserved three-dimensional structure in the vertebrate Irx clusters facilitates enhancer sharing and coregulation. *Nat Commun.* 2011;2:310.
39. Altshuler D, Daly MJ, Lander ES. Genetic mapping in human disease. *Science.* 2008;322(5903):881–888.
40. Probst V, et al. Haploinsufficiency in combination with aging causes SCN5A-linked hereditary Lenege disease. *J Am Coll Cardiol.* 2003;41(4):643–652.
41. Hindorff LA, et al. Potential etiologic and functional implications of genome-wide association loci for human diseases and traits. *Proc Natl Acad Sci U S A.* 2009;106(23):9362–9367.
42. Maurano MT, et al. Systematic localization of common disease-associated variation in regulatory DNA. *Science.* 2012;337(6099):1190–1195.
43. Simonis M, Kooren J, de Laat W. An evaluation of 3C-based methods to capture DNA interactions. *Nat Methods.* 2007;4(11):895–901.
44. Montgomery KT, et al. Mutation detection using automated fluorescence-based sequencing. *Curr Protoc Hum Genet.* 2008;Chapter 7:Unit 7.9.
45. Shabalín AA. Matrix eQTL: ultra fast eQTL analysis via large matrix operations. *Bioinformatics.* 2012;28(10):1353–1358.
46. Vandesompele J, et al. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. *Genome Biol.* 2002;3(7):RESEARCH0034.
47. Schmittgen TD, Zakrajsek BA, Mills AG, Gorn V, Singer MJ, Reed MW. Quantitative reverse transcription-polymerase chain reaction to study mRNA decay: comparison of endpoint and real-time methods. *Anal Biochem.* 2000;285(2):194–204.